A 38-year-old woman presents with a 6-month history of a rapidly enlarging mass in the left breast with overlying skin erythema and edema. On examination, the breast is warm, tender, and the skin shows peau d'orange appearance. Axillary lymph nodes are enlarged and firm. Core needle biopsy shows invasive carcinoma with marked nuclear pleomorphism, high mitotic rate (>20 per 10 HPF), and central necrosis. Immunohistochemistry: ER−, PR−, HER2 3+ (FISH positive). What is the most likely diagnosis and the recommended first-line systemic therapy?

Explanation

## Clinical Diagnosis: Inflammatory Breast Cancer (IBC) ### Diagnostic Criteria **Key Point:** This patient meets **all hallmark features of inflammatory breast cancer**: | Feature | Patient Presentation | IBC Criterion | |---------|---------------------|---------------| | **Onset** | 6 months (rapid) | Rapid progression (weeks to months) | | **Skin findings** | Erythema, edema, peau d'orange | Dermal lymphatic invasion by tumor | | **Breast appearance** | Warm, tender, edematous | Inflammatory clinical phenotype | | **Lymph nodes** | Enlarged, firm | Regional nodal involvement (N3) | | **Histology** | High-grade, necrosis | Aggressive biology | | **HER2 status** | 3+/FISH+ | ~40% of IBC are HER2+ | ### Pathological Features **High-Yield:** The biopsy shows: - **Marked nuclear pleomorphism** — high-grade malignancy - **>20 mitotic figures per 10 HPF** — extremely aggressive - **Central necrosis** — rapid growth outpacing blood supply - **ER−/PR−/HER2 3+** — triple-negative-like phenotype with HER2 amplification; **HER2+ IBC has worse prognosis than HER2− IBC** **Warning:** Do NOT confuse IBC with simple mastitis or cellulitis — the presence of **dermal lymphatic invasion on histology** is pathognomonic. Clinical diagnosis requires skin involvement (erythema, edema, peau d'orange) + biopsy confirmation. ### Staging & Prognosis **Clinical Pearl:** All inflammatory breast cancers are classified as **stage IIIB or IV** (AJCC) by definition, regardless of tumor size or nodal status, because of the aggressive biology and early systemic spread. 5-year survival is ~40% with multimodal therapy. ### Treatment Algorithm ```mermaid flowchart TD A[Inflammatory Breast Cancer]:::outcome --> B{HER2 status?}:::decision B -->|HER2+| C[Trastuzumab + pertuzumab + chemotherapy]:::action B -->|HER2−| D[Chemotherapy alone]:::action C --> E[Neoadjuvant therapy]:::action D --> E E --> F[Reassess for surgery]:::decision F -->|Responsive| G[Mastectomy + axillary dissection]:::action F -->|Refractory| H[Radiation + continued systemic therapy]:::action G --> I[Adjuvant radiation + continued systemic therapy]:::action ``` ### First-Line Systemic Therapy **High-Yield:** For HER2+ IBC, the standard of care is: 1. **Trastuzumab** (anti-HER2 monoclonal antibody) — targets HER2 overexpression 2. **Pertuzumab** (HER2 dimerization inhibitor) — synergistic with trastuzumab 3. **Chemotherapy** (taxane-based, e.g., docetaxel or paclitaxel) — backbone of neoadjuvant regimen **Mnemonic:** **HER2+ IBC = TPT** (Trastuzumab + Pertuzumab + Taxane) This is **neoadjuvant therapy** (given before surgery) to downstage the tumor and assess response. Surgery (mastectomy with axillary dissection) follows if there is adequate response. ### Why HER2+ Matters in IBC **Clinical Pearl:** HER2 amplification in IBC is associated with: - Increased growth factor signaling (EGFR, HER2, HER3 cross-talk) - Enhanced angiogenesis and lymphangiogenesis (explains peau d'orange) - Greater chemosensitivity to taxanes - Dramatic improvement in survival with dual HER2 blockade (trastuzumab + pertuzumab) Without anti-HER2 therapy, HER2+ IBC has dismal outcomes.